Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Cabaletta Bio Inc (CABA)

Cabaletta Bio Inc (CABA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 91,400
  • Shares Outstanding, K 48,877
  • Annual Sales, $ 0 K
  • Annual Income, $ -67,680 K
  • EBIT $ -115 M
  • EBITDA $ -114 M
  • 60-Month Beta 2.42
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.52

Options Overview Details

View History
  • Implied Volatility 146.86% ( -66.39%)
  • Historical Volatility 134.14%
  • IV Percentile 74%
  • IV Rank 10.85%
  • IV High 861.91% on 08/12/24
  • IV Low 59.81% on 07/31/24
  • Put/Call Vol Ratio 0.03
  • Today's Volume 367
  • Volume Avg (30-Day) 244
  • Put/Call OI Ratio 0.17
  • Today's Open Interest 5,667
  • Open Int (30-Day) 5,609

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 12 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.64
  • Number of Estimates 5
  • High Estimate -0.55
  • Low Estimate -0.70
  • Prior Year -0.46
  • Growth Rate Est. (year over year) -39.13%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.7600 +30.11%
on 11/21/24
4.7500 -51.79%
on 11/06/24
-1.6200 (-41.43%)
since 10/25/24
3-Month
1.7600 +30.11%
on 11/21/24
6.2200 -63.18%
on 08/26/24
-3.7700 (-62.21%)
since 08/23/24
52-Week
1.7600 +30.11%
on 11/21/24
26.3500 -91.31%
on 02/08/24
-16.3800 (-87.73%)
since 11/24/23

Most Recent Stories

More News
2 Penny Stocks That Wall Street Predicts Will Soar 306% to 1,183% in 2025

Both penny stocks are a 'strong buy' on Wall Street.

CABA : 2.2900 (+22.46%)
$SPX : 5,987.37 (+0.30%)
NTLA : 14.79 (+3.43%)
Cabaletta Bio Presents Positive Clinical Safety and Efficacy Data on CABA-201 at ACR Convergence 2024

CABA : 2.2900 (+22.46%)
Cabaletta Bio Reports Third Quarter 2024 Financial Results and Provides Business Update

CABA : 2.2900 (+22.46%)
Cabaletta Bio to Participate in Guggenheim’s Inaugural Healthcare Innovation Conference

CABA : 2.2900 (+22.46%)
Why Shares of Cabaletta Bio Are Up Tuesday

The biotech stock rose after an analyst upgrade.

CABA : 2.2900 (+22.46%)
Cabaletta Bio Reports Second Quarter 2022 Financial Results and Provides Business Update

PHILADELPHIA, Aug. 11, 2022 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and...

CABA : 2.2900 (+22.46%)
Cabaletta Bio Presents Updated Interim DesCAARTes™ Trial Phase 1 Data at the ASGCT 25th Annual Meeting

PHILADELPHIA, May 18, 2022 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and...

CABA : 2.2900 (+22.46%)
Cabaletta Bio Reports First Quarter 2022 Financial Results and Provides Business Update

– DesCAARTes™ trial clinical and translational data from cohorts A3 and A4 and 28-day safety data from cohort A5 expected to be presented at upcoming...

CABA : 2.2900 (+22.46%)
Cabaletta Bio to Present DSG3-CAART Clinical Data and MuSK-CAART Preclinical Data at Upcoming Scientific Meetings in May

PHILADELPHIA, May 02, 2022 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and...

CABA : 2.2900 (+22.46%)
CABALETTA DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Cabaletta Bio, Inc. and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, reminds investors that a class action lawsuit has been filed against Cabaletta Bio, Inc. (“Cabaletta” or the “Company”)...

CABA : 2.2900 (+22.46%)

Business Summary

Cabaletta Bio Inc. is a clinical stage biotechnology company. It is focused on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. The company's product pipeline consists of DSG3-CAART, DSG3/1-CAART, MuSK-CAART and FVIII-CAART which are...

See More

Key Turning Points

3rd Resistance Point 3.1400
2nd Resistance Point 2.8200
1st Resistance Point 2.5500
Last Price 2.2900
1st Support Level 1.9600
2nd Support Level 1.6400
3rd Support Level 1.3700

See More

52-Week High 26.3500
Fibonacci 61.8% 16.9600
Fibonacci 50% 14.0600
Fibonacci 38.2% 11.1500
Last Price 2.2900
52-Week Low 1.7600

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar